Movement Alert｜Hengrui Medicine Rises 3.28% in Regular Trading, ASCO Showcase and Buyback Resumption Boost Sentiment

Market Focus06-05 09:51

On June 5, Hengrui Medicine (01276.HK) rose 3.28% in regular trading, trading at HK$55.95/share, with trading volume of HK$95.28 million. Multiple positive catalysts converged to drive the rebound after a roughly 34% pullback from prior highs.

On the news front, Hengrui Medicine delivered its strongest-ever presence at the ASCO Annual Meeting with 91 oncology research results selected — the highest among Chinese pharmaceutical companies — including 11 oral presentations covering gastrointestinal tumors, breast cancer, lung cancer, and urological cancers. Key highlights include a global-first positive Phase III result for its HER3 ADC (SHR-A2009) in EGFR-mutant lung cancer, and significant PFS improvements for its HER2 ADC in colorectal cancer. Simultaneously, the company resumed its buyback program on June 4, repurchasing 420,000 A-shares for approximately RMB 19.82 million at prices between RMB 46.70–47.70 per share, with cumulative buybacks reaching RMB 772 million. The company reported Q1 revenue of RMB 8.14 billion (+12.98% YoY) and net profit of RMB 2.28 billion (+21.78% YoY), reinforcing its growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177914647?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177914647","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.28% in Regular Trading, ASCO Showcase and Buyback Resumption Boost Sentiment","media":"Market Focus","content":"<p><p>On June 5, Hengrui Medicine (01276.HK) rose 3.28% in regular trading, trading at HK$55.95/share, with trading volume of HK$95.28 million. Multiple positive catalysts converged to drive the rebound after a roughly 34% pullback from prior highs.</p><p>On the news front, Hengrui Medicine delivered its strongest-ever presence at the ASCO Annual Meeting with 91 oncology research results selected — the highest among Chinese pharmaceutical companies — including 11 oral presentations covering gastrointestinal tumors, breast cancer, lung cancer, and urological cancers. Key highlights include a global-first positive Phase III result for its HER3 ADC (SHR-A2009) in EGFR-mutant lung cancer, and significant PFS improvements for its HER2 ADC in colorectal cancer. Simultaneously, the company resumed its buyback program on June 4, repurchasing 420,000 A-shares for approximately RMB 19.82 million at prices between RMB 46.70–47.70 per share, with cumulative buybacks reaching RMB 772 million. The company reported Q1 revenue of RMB 8.14 billion (+12.98% YoY) and net profit of RMB 2.28 billion (+21.78% YoY), reinforcing its growth trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.28% in Regular Trading, ASCO Showcase and Buyback Resumption Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.28% in Regular Trading, ASCO Showcase and Buyback Resumption Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Hengrui Medicine (01276.HK) rose 3.28% in regular trading, trading at HK$55.95/share, with trading volume of HK$95.28 million. Multiple positive catalysts converged to drive the rebound after a roughly 34% pullback from prior highs.</p><p>On the news front, Hengrui Medicine delivered its strongest-ever presence at the ASCO Annual Meeting with 91 oncology research results selected — the highest among Chinese pharmaceutical companies — including 11 oral presentations covering gastrointestinal tumors, breast cancer, lung cancer, and urological cancers. Key highlights include a global-first positive Phase III result for its HER3 ADC (SHR-A2009) in EGFR-mutant lung cancer, and significant PFS improvements for its HER2 ADC in colorectal cancer. Simultaneously, the company resumed its buyback program on June 4, repurchasing 420,000 A-shares for approximately RMB 19.82 million at prices between RMB 46.70–47.70 per share, with cumulative buybacks reaching RMB 772 million. The company reported Q1 revenue of RMB 8.14 billion (+12.98% YoY) and net profit of RMB 2.28 billion (+21.78% YoY), reinforcing its growth trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1177914647","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177914647","pubTimestamp":1780624307,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Hengrui Medicine (01276.HK) rose 3.28% in regular trading, trading at HK$55.95/share, with trading volume of HK$95.28 million. Multiple positive catalysts converged to drive the rebound...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动向提示|恒瑞医药常规交易涨3.28%ASCO展示及回购恢复提振人气","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On June 5, Hengrui Medicine (01276.HK) rose 3.28% in regular trading, trading at HK$55.95/share, with trading volume of HK$95.28 million. Multiple positive catalysts converged to drive the rebound after a roughly 34% pullback from prior highs.On the news front, Hengrui Medicine delivered its strongest-ever presence at the ASCO Annual Meeting with 91 oncology research results selected — the highest among Chinese pharmaceutical companies — including 11 oral presentations covering gastrointestinal tumors, breast cancer, lung cancer, and urological cancers. Key highlights include a global-first positive Phase III result for its HER3 ADC (SHR-A2009) in EGFR-mutant lung cancer, and significant PFS improvements for its HER2 ADC in colorectal cancer. Simultaneously, the company resumed its buyback program on June 4, repurchasing 420,000 A-shares for approximately RMB 19.82 million at prices between RMB 46.70–47.70 per share, with cumulative buybacks reaching RMB 772 million. The company reported Q1 revenue of RMB 8.14 billion (+12.98% YoY) and net profit of RMB 2.28 billion (+21.78% YoY), reinforcing its growth trajectory.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177914647","isCrawlerRequest":true}